A Phase 3 interventional study of Brexpiprazole and Brexpiprazole in Alzheimer's Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 55 Years to 91 Years. Per ClinicalTrials.gov, last updated 2023-11-14.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 13 in phase 3, and was the 14th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15+
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 91 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 259 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 265 across the 12 interventional studies, 450 across the 3 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
1 of the studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06875986Otsuka Pharmaceutical Co., Ltd.REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Active treatment extension study of the 331-14-213 trial, to assess the long-term safety and tolerability of oral brexpiprazole as treatment in adult participants with agitation associated with dementia of the Alzheimer's type (AAD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who received brexpiprazole in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received the same dose of brexpiprazole \[2 or 3 milligrams (mg)\], once daily (QD), orally, as they received during the previous study, for up to 12 weeks with dose adjustment.
Drug: Brexpiprazole
Participants who received placebo in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received brexpiprazole following a titration schedule, to gradually increase their dose from 0.5 mg QD, in the starting to 2 or 3 mg QD, orally, for up to 12 weeks with dose adjustment.
Drug: Brexpiprazole
2 or 3 mg tablet
0.5 to 3 mg tablet
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity
An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with an onset date on or after the first dose of brexpiprazole. They are all adverse events that started after start of brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy. Adverse events were graded on a 3-point scale. The intensity of an adverse experience was defined as follows: 1 = Mild: Discomfort noticed, but no disruption to daily activity, 2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity, and 3 = Severe: Inability to work or perform normal daily activity.
Time frame: From first dose through 30 days after last dose of study drug (Up to approximately Week 16)
This study was conducted at 66 sites from 11 October 2018 to 19 September 2022 in the following countries: Bulgaria, Hungary, Serbia, Slovakia, Spain, Ukraine, and the United States.
| Milestone | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Started | 163 | 96 |
| Efficacy sample: | 159 | 95 |
| Completed | 142 | 87 |
| Not completed | 21 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 8 | 5 |
| Withdrew: Site terminated by sponsor | 4 | 1 |
| Withdrew: Subject withdrew consent to participate | 7 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Other (not related to covid-19) | 1 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with an onset date on or after the first dose of brexpiprazole. They are all adverse events that started after start of brexpiprazole; or if the event was continuous from baseline and was worsening, serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy. Adverse events were graded on a 3-point scale. The intensity of an adverse experience was defined as follows: 1 = Mild: Discomfort noticed, but no disruption to daily activity, 2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity, and 3 = Severe: Inability to work or perform normal daily activity.
| percentage of participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Mild | 20.9 | 13.5 |
| Moderate | 9.2 | 19.8 |
| Severe | 3.1 | 0 |
Collected over From first dose through 30 days after last dose of study drug (Up to approximately Week 16). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior Brexpiprazole | 0/163 (0%) | 6/163 (3.7%) | 0/163 (0%) |
| Prior Placebo | 0/96 (0%) | 0/96 (0%) | 5/96 (5.2%) |
| Event | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 3/163 | 0/96 |
| Blood Loss AnaemiaBlood and lymphatic system disorders | 1/163 | 0/96 |
| HaemorrhoidsGastrointestinal disorders | 1/163 | 0/96 |
| Femur FractureInjury, poisoning and procedural complications | 1/163 | 0/96 |
| Hip FractureInjury, poisoning and procedural complications | 1/163 | 0/96 |
| Hepatic Enzyme IncreasedInvestigations | 1/163 | 0/96 |
| SyncopeNervous system disorders | 1/163 | 0/96 |
| Event | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 0/163 | 5/96 |
Randomized sample comprised of all participants randomized into this trial. As prespecified in the SAP, data was analyzed based on the treatments (Brexpiprazole or Placebo) received in parent study 331-14-213. Participants received brexpiprazole 2 or 3 mg or placebo in the parent study, data for this study was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| Age, Continuous(years) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 74.8 ± 7.9 | 73.4 ± 73.0 | 74.3 ± 75.0 |
| Sex: Female, Male(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Female | 99 | 46 | 145 |
| Male | 64 | 50 | 114 |
| Ethnicity (NIH/OMB)(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 52 | 30 | 82 |
| Not Hispanic or Latino | 111 | 66 | 177 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 1 | 8 |
| White | 154 | 94 | 248 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Bulgaria | 15 | 11 | 26 |
| Hungary | 3 | 2 | 5 |
| Serbia | 9 | 8 | 17 |
| Slovakia | 5 | 3 | 8 |
| Spain | 5 | 3 | 8 |
| Ukraine | 55 | 31 | 86 |
| United States | 71 | 38 | 109 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Oct 2018 to primary completion in Sep 2022, 47 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 47 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →